<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350336</url>
  </required_header>
  <id_info>
    <org_study_id>10-02</org_study_id>
    <nct_id>NCT01350336</nct_id>
  </id_info>
  <brief_title>Bronchial Thermoplasty in Severe Persistent Asthma</brief_title>
  <acronym>PAS2</acronym>
  <official_title>Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As Conditions of Approval of the PMA for the Alair System, the FDA requires Boston Scientific&#xD;
      to generate data to assess the durability of the BT treatment effect as well as safety data&#xD;
      in the intended use population in the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, single arm study designed to demonstrate durability of the&#xD;
      treatment effect and to evaluate the short-term and longer-term safety profile of the Alair&#xD;
      System in the United States in the intended use population (patients 18 years and older with&#xD;
      severe persistent asthma).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2011</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">November 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects Experiencing Severe Exacerbations (Rates)</measure>
    <time_frame>Year 1 vs. Year 2, 3, 4, 5</time_frame>
    <description>The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the subsequent 12-month (for Years 2, 3, 4, and 5) compared to the first 12-month after the Alair treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Severe Exacerbations</measure>
    <time_frame>Year 1-5</time_frame>
    <description># Severe exacerbations / subject / year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Adverse Event Rates</measure>
    <time_frame>Year 1-5</time_frame>
    <description>A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Respiratory Adverse Events</measure>
    <time_frame>Year 1-5</time_frame>
    <description>A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Room Visits for Respiratory Symptoms Rates</measure>
    <time_frame>Year 1-5</time_frame>
    <description>Emergency room visits for respiratory symptoms (rates of emergency room visits)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Emergency Room Visits for Respiratory Symptoms</measure>
    <time_frame>Year 1-5</time_frame>
    <description>Subjects with Emergency room visits for respiratory symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations for Respiratory Symptoms Rates</measure>
    <time_frame>Year 1-5</time_frame>
    <description>(# hospitalizations for respiratory symptoms / subject / year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Hospitalizations for Respiratory Symptoms</measure>
    <time_frame>Year 1-5</time_frame>
    <description>Subjects with hospitalizations for respiratory symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Serious Adverse Events Rates</measure>
    <time_frame>Year 1-5</time_frame>
    <description>The rate of subjects with respiratory serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Respiratory Serious Adverse Events</measure>
    <time_frame>Year 1-5</time_frame>
    <description>Subjects with Respiratory Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator FEV1</measure>
    <time_frame>Year 1-5</time_frame>
    <description>% Predicted Pre-bronchodilator FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1</measure>
    <time_frame>Year 1-5</time_frame>
    <description>% Predicted Post-bronchodilator FEV1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Severe Asthma</condition>
  <arm_group>
    <arm_group_label>Alair</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alair system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alair System</intervention_name>
    <description>Treatment of airways with the Alair System</description>
    <arm_group_label>Alair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is an adult between the ages of 18 to 65 years.&#xD;
&#xD;
          2. Subject is able to read, understand, and sign a written Informed Consent to&#xD;
             participate in the study and able to comply with the study protocol.&#xD;
&#xD;
          3. Subject has asthma and is taking regular maintenance medication that includes:&#xD;
&#xD;
               1. Inhaled corticosteroid (ICS) at a dosage greater than 1000μg beclomethasone per&#xD;
                  day or equivalent, AND long acting β2-agonist (LABA) at a dosage of ≥80μg per day&#xD;
                  Salmeterol or equivalent.&#xD;
&#xD;
               2. Other asthma medications such as leukotriene modifiers, or anti-IgE, are&#xD;
                  acceptable (Subjects on Xolair® must have been on Xolair for greater than 1&#xD;
                  year).&#xD;
&#xD;
               3. Oral corticosteroids (OCS) at a dosage of up to, but not greater than 10mg per&#xD;
                  day are acceptable.*&#xD;
&#xD;
          4. Subject has a pre-bronchodilator FEV1 of greater than or equal to 60% of predicted.&#xD;
&#xD;
          5. Subject is a non-smoker for 1 year or greater (if former smoker, less than 10 pack&#xD;
             years total smoking history).&#xD;
&#xD;
          6. Subject is able to undergo outpatient (same day) bronchoscopy in the opinion of the&#xD;
             investigator or per hospital guidelines.&#xD;
&#xD;
          7. Subject has at least 2 days of asthma symptoms in the last 4 weeks.&#xD;
&#xD;
          8. Subject has an AQLQ score during the baseline period of 6.25 or less.&#xD;
&#xD;
               -  NOTE: Subjects on a dosage regimen of 20mg OCS every other day may be included as&#xD;
                  this is equivalent to an average daily dosage of 10mg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is participating in another clinical trial within 6 weeks of the Baseline&#xD;
             Period involving respiratory intervention that could affect the outcome measures of&#xD;
             this Study.&#xD;
&#xD;
          2. Over the last 7 days of a 4 week medication stable period, subject requirement for&#xD;
             rescue medication use other than for prophylactic use for exercise exceeds an average&#xD;
             of:&#xD;
&#xD;
               1. 8 puffs per day of short-acting bronchodilator, or&#xD;
&#xD;
               2. 4 puffs per day of long-acting rescue bronchodilator, or&#xD;
&#xD;
               3. 2 nebulizer treatments per day. At the discretion of the Principal Investigator,&#xD;
                  subjects considered as unstable on baseline medications may have medications&#xD;
                  adjusted and re-evaluated after a 4 week medication stabilization period.&#xD;
&#xD;
          3. Subject has a post-bronchodilator FEV1 of less than 65%.&#xD;
&#xD;
          4. Subject has a history of life-threatening asthma, defined by past intubation for&#xD;
             asthma, or ICU admission for asthma within the prior 2 years.&#xD;
&#xD;
          5. Subject has 3 or more hospitalizations for exacerbations of asthma in the previous&#xD;
             year.&#xD;
&#xD;
          6. Subject has had 4 or more infections of lower respiratory tract (LRTI) requiring&#xD;
             antibiotics in the past 12 months.&#xD;
&#xD;
          7. Subject has had 4 or more pulses of systemic corticosteroids (tablets, suspension or&#xD;
             injection) for asthma symptoms in the past 12 months.&#xD;
&#xD;
          8. Subject has a known sensitivity to medications required to perform bronchoscopy (such&#xD;
             as lidocaine, atropine and benzodiazepines).&#xD;
&#xD;
          9. Subject has other respiratory diseases including emphysema, cystic fibrosis, vocal&#xD;
             cord dysfunction, mechanical upper airway obstruction, Churg-Strauss syndrome, and&#xD;
             allergic bronchopulmonary aspergillosis (asthma, immediate cutaneous reactivity to A.&#xD;
             fumigatus, total serum IgE of &gt;1000ng/mL, elevated specific IgE and IgG to A.&#xD;
             fumigatus with or without evidence of central bronchiectasis).&#xD;
&#xD;
         10. Subject has segmental atelectasis, lobar consolidation, significant or unstable&#xD;
             pulmonary infiltrate, or pneumothorax, confirmed on x-ray.&#xD;
&#xD;
         11. Subject currently has clinically significant cardiovascular disease, including&#xD;
             myocardial infarction, angina, cardiac dysfunction, cardiac dysrhythmia, conduction&#xD;
             defect, cardiomyopathy, or stroke.&#xD;
&#xD;
         12. Subject has a known aortic aneurysm.&#xD;
&#xD;
         13. Subject has significant co-morbid illness such as cancer, renal failure, liver&#xD;
             disease, or cerebral vascular disease.&#xD;
&#xD;
         14. Subject has uncontrolled hypertension (&gt;200mm Hg systolic or &gt;100mm Hg diastolic&#xD;
             pressure).&#xD;
&#xD;
         15. Subject has an implanted electrical stimulation device (e.g., a pacemaker, cardiac&#xD;
             defibrillator, or deep nerve or deep brain stimulator).&#xD;
&#xD;
         16. Subject has coagulopathy (INR &gt; 1.5).&#xD;
&#xD;
         17. Subject has any other medical condition that would make them inappropriate for study&#xD;
             participation, in the Investigator's opinion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas S Bowman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Lung Health Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Center for Asthma and Airway Disease</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Specialty Center, Lung and Sleep Health</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DuBois Regional Medical Center</name>
      <address>
        <city>DuBois</city>
        <state>Pennsylvania</state>
        <zip>15801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State Hershey</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Research Center (St. Joseph Medical Center)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Pulmonary Specialists</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surrey Memorial Hospital</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3T 0G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital, University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Laval Centre de Pneumologie</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.btforasthma.com/</url>
    <description>Bronchial Thermoplasty</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>February 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 13, 2021</last_update_submitted>
  <last_update_submitted_qc>February 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Following Last Patient Out, when Results are posted.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT01350336/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 26, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT01350336/Prot_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alair</title>
          <description>Participants consented for treatment with Alair</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects with at least 1 BT procedure.</population>
      <group_list>
        <group group_id="B1">
          <title>Alair</title>
          <description>Alair system&#xD;
Alair System: Treatment of airways with the Alair System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="279"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.71" lower_limit="18" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, of African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.4" lower_limit="133" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.3" lower_limit="49" upper_limit="185.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" lower_limit="18.2" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AQLQ</title>
          <description>There are 32 questions in the Asthma Quality of Life Questionnaire (AQLQ) and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains.</description>
          <units>AQLQ Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.03" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 - % Predicted</title>
          <units>% Predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Pre-bronchodilator FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.4" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-bronchodilator FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.8" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior 12 months - % Subjects</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Severe Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER visits for asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior 12 months - Event rates</title>
          <units># events / subject</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Severe Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.61" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalizations for asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.22" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER visits for asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.54" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects Experiencing Severe Exacerbations (Rates)</title>
        <description>The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the subsequent 12-month (for Years 2, 3, 4, and 5) compared to the first 12-month after the Alair treatment.</description>
        <time_frame>Year 1 vs. Year 2, 3, 4, 5</time_frame>
        <population>Primary Endpoint - the proportion of subjects experiencing severe exacerbations during the subsequent 12-month (for Years 2, 3, 4, and 5) compared to the first 12-month after the Alair treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Proportion of Severe Exacerbations at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Proportion of Severe Exacerbations at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Proportion of Severe Exacerbations at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Proportion of Severe Exacerbations at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Proportion of Severe Exacerbations at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Experiencing Severe Exacerbations (Rates)</title>
          <description>The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the subsequent 12-month (for Years 2, 3, 4, and 5) compared to the first 12-month after the Alair treatment.</description>
          <population>Primary Endpoint - the proportion of subjects experiencing severe exacerbations during the subsequent 12-month (for Years 2, 3, 4, and 5) compared to the first 12-month after the Alair treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="106"/>
                    <measurement group_id="O5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Years 1 and 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>An upper 95% confidence limit of the difference between Year 2 compared to the first 12-month proportion is less than 20% will demonstrate that the proportions are not substantially worse during each of the subsequent evaluation periods.</non_inferiority_desc>
            <param_type>Difference of proportions</param_type>
            <param_value>-0.0380</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1251</ci_lower_limit>
            <ci_upper_limit>0.0497</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Years 1 and 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>An upper 95% confidence limit of the difference between Year 3 compared to the first 12-month proportion is less than 20% will demonstrate that the proportions are not substantially worse during each of the subsequent evaluation periods.</non_inferiority_desc>
            <param_type>Difference of proportions</param_type>
            <param_value>-0.0325</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1197</ci_lower_limit>
            <ci_upper_limit>0.0565</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Years 1 and 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>An upper 95% confidence limit of the difference between Year 4 compared to the first 12-month proportion is less than 20% will demonstrate that the proportions are not substantially worse during each of the subsequent evaluation periods.</non_inferiority_desc>
            <param_type>Difference of proportions</param_type>
            <param_value>-0.0566</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1444</ci_lower_limit>
            <ci_upper_limit>0.0329</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of Years 1 and 5</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>An upper 95% confidence limit of the difference between Year 5 compared to the first 12-month proportion is less than 20% will demonstrate that the proportions are not substantially worse during each of the subsequent evaluation periods.</non_inferiority_desc>
            <param_type>Difference of proportions</param_type>
            <param_value>-0.0765</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1661</ci_lower_limit>
            <ci_upper_limit>0.0130</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Severe Exacerbations</title>
        <description># Severe exacerbations / subject / year</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Rates of Severe Exacerbations at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Rates of Severe Exacerbations at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Rates of Severe Exacerbations at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Rates of Severe Exacerbations at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Rates of Severe Exacerbations at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Severe Exacerbations</title>
          <description># Severe exacerbations / subject / year</description>
          <units># Severe Exacerbations / subject / year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.35"/>
                    <measurement group_id="O2" value=".92" spread="1.21"/>
                    <measurement group_id="O3" value=".77" spread="1.01"/>
                    <measurement group_id="O4" value=".84" spread="1.23"/>
                    <measurement group_id="O5" value=".72" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Adverse Event Rates</title>
        <description>A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Respiratory adverse events at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Respiratory adverse events at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Respiratory adverse events at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Respiratory adverse events at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Respiratory adverse events at Year</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Adverse Event Rates</title>
          <description>A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
          <units># Resp. AE / subject / year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="250"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="1.95"/>
                    <measurement group_id="O2" value="1.52" spread="1.66"/>
                    <measurement group_id="O3" value="1.28" spread="1.42"/>
                    <measurement group_id="O4" value="1.35" spread="1.63"/>
                    <measurement group_id="O5" value="1.22" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Respiratory Adverse Events</title>
        <description>A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Respiratory adverse events at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Respiratory adverse events at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Respiratory adverse events at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Respiratory adverse events at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Respiratory adverse events at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Respiratory Adverse Events</title>
          <description>A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="250"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="165"/>
                    <measurement group_id="O3" value="155"/>
                    <measurement group_id="O4" value="141"/>
                    <measurement group_id="O5" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Room Visits for Respiratory Symptoms Rates</title>
        <description>Emergency room visits for respiratory symptoms (rates of emergency room visits)</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Emergency room visits for respiratory symptoms rates at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Emergency room visits for respiratory symptoms rates at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Emergency room visits for respiratory symptoms rates at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Emergency room visits for respiratory symptoms rates at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Emergency room visits for respiratory symptoms rates at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Room Visits for Respiratory Symptoms Rates</title>
          <description>Emergency room visits for respiratory symptoms (rates of emergency room visits)</description>
          <units># ER Visit / subject / year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".31" spread=".87"/>
                    <measurement group_id="O2" value=".24" spread=".80"/>
                    <measurement group_id="O3" value=".21" spread=".65"/>
                    <measurement group_id="O4" value=".17" spread=".56"/>
                    <measurement group_id="O5" value=".13" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Emergency Room Visits for Respiratory Symptoms</title>
        <description>Subjects with Emergency room visits for respiratory symptoms</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Emergency room visits for respiratory symptoms proportions at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Emergency room visits for respiratory symptoms proportions at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Emergency room visits for respiratory symptoms proportions at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Emergency room visits for respiratory symptoms proportions at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Emergency room visits for respiratory symptoms proportions at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Emergency Room Visits for Respiratory Symptoms</title>
          <description>Subjects with Emergency room visits for respiratory symptoms</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalizations for Respiratory Symptoms Rates</title>
        <description>(# hospitalizations for respiratory symptoms / subject / year)</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Hospitalizations for respiratory symptoms rates at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Hospitalizations for respiratory symptoms rates at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Hospitalizations for respiratory symptoms rates at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Hospitalizations for respiratory symptoms rates at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Hospitalizations for respiratory symptoms rates at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations for Respiratory Symptoms Rates</title>
          <description>(# hospitalizations for respiratory symptoms / subject / year)</description>
          <units># Hospitalizations / subject / year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.50"/>
                    <measurement group_id="O2" value="0.11" spread="0.47"/>
                    <measurement group_id="O3" value="0.11" spread="0.47"/>
                    <measurement group_id="O4" value="0.05" spread="0.28"/>
                    <measurement group_id="O5" value="0.06" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Hospitalizations for Respiratory Symptoms</title>
        <description>Subjects with hospitalizations for respiratory symptoms</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Hospitalizations for respiratory symptoms proportions at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Hospitalizations for respiratory symptoms proportions at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Hospitalizations for respiratory symptoms proportions at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Hospitalizations for respiratory symptoms proportions at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Hospitalizations for respiratory symptoms proportions at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Hospitalizations for Respiratory Symptoms</title>
          <description>Subjects with hospitalizations for respiratory symptoms</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Serious Adverse Events Rates</title>
        <description>The rate of subjects with respiratory serious adverse events (SAEs)</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Respiratory Serious Adverse Events rates at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Respiratory Serious Adverse Events rates at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Respiratory Serious Adverse Events rates at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Respiratory Serious Adverse Events rates at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Respiratory Serious Adverse Events rates at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Serious Adverse Events Rates</title>
          <description>The rate of subjects with respiratory serious adverse events (SAEs)</description>
          <units># Respiratory SAEs / subect / year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="250"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.50"/>
                    <measurement group_id="O2" value="0.11" spread="0.37"/>
                    <measurement group_id="O3" value="0.10" spread="0.41"/>
                    <measurement group_id="O4" value="0.06" spread="0.33"/>
                    <measurement group_id="O5" value="0.06" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Respiratory Serious Adverse Events</title>
        <description>Subjects with Respiratory Serious Adverse Events</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Respiratory Serious Adverse Events proportions at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Respiratory Serious Adverse Events proportions at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Respiratory Serious Adverse Events proportions at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Respiratory Serious Adverse Events proportions at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Respiratory Serious Adverse Events proportions at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Respiratory Serious Adverse Events</title>
          <description>Subjects with Respiratory Serious Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="250"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator FEV1</title>
        <description>% Predicted Pre-bronchodilator FEV1</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Respiratory Serious Adverse Events proportions at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Respiratory Serious Adverse Events proportions at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Respiratory Serious Adverse Events proportions at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Respiratory Serious Adverse Events proportions at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Respiratory Serious Adverse Events proportions at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator FEV1</title>
          <description>% Predicted Pre-bronchodilator FEV1</description>
          <units>% Predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="235"/>
                <count group_id="O4" value="212"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" spread="14.5"/>
                    <measurement group_id="O2" value="89.3" spread="14.6"/>
                    <measurement group_id="O3" value="87.7" spread="14.9"/>
                    <measurement group_id="O4" value="88.5" spread="13.8"/>
                    <measurement group_id="O5" value="87.4" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FEV1</title>
        <description>% Predicted Post-bronchodilator FEV1</description>
        <time_frame>Year 1-5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Year 1</title>
            <description>Respiratory Serious Adverse Events proportions at Year 1</description>
          </group>
          <group group_id="O2">
            <title>Year 2</title>
            <description>Respiratory Serious Adverse Events proportions at Year 2</description>
          </group>
          <group group_id="O3">
            <title>Year 3</title>
            <description>Respiratory Serious Adverse Events proportions at Year 3</description>
          </group>
          <group group_id="O4">
            <title>Year 4</title>
            <description>Respiratory Serious Adverse Events proportions at Year 4</description>
          </group>
          <group group_id="O5">
            <title>Year 5</title>
            <description>Respiratory Serious Adverse Events proportions at Year 5</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FEV1</title>
          <description>% Predicted Post-bronchodilator FEV1</description>
          <units>% Predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="212"/>
                <count group_id="O5" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" spread="13.9"/>
                    <measurement group_id="O2" value="92.3" spread="14.1"/>
                    <measurement group_id="O3" value="91.8" spread="14.2"/>
                    <measurement group_id="O4" value="91.1" spread="14.4"/>
                    <measurement group_id="O5" value="91.0" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 Years</time_frame>
      <desc>Adverse events were collected from the time of first BT procedure through the 5-year follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alair</title>
          <description>Alair system&#xD;
Alair System: Treatment of airways with the Alair System</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Tooth malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Aspergilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood immunoglobulin G decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Delivery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="135" subjects_affected="58" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Vocal cord disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Excessive skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="33" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="205" subjects_affected="118" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="152" subjects_affected="89" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="140" subjects_affected="64" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="80" subjects_affected="48" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="71" subjects_affected="40" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="48" subjects_affected="38" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="37" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="42" subjects_affected="28" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="23" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1258" subjects_affected="234" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="78" subjects_affected="54" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="63" subjects_affected="40" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>G Mark Grubb</name_or_title>
      <organization>Boston Scientific Corp.</organization>
      <phone>(412) 716-0717</phone>
      <email>grubbm@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

